TCRX TScan Therapeutics, Inc.

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

$2.66  -0.24 (-8.28%)
As of 09/22/2022 16:30:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  07/16/2021
Outstanding shares:  18,929,834
Average volume:  19,969
Market cap:   $54,517,922
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      
Valuation   (See tab for details)
PE ratio:   -0.89
PB ratio:   0.44
PS ratio:   4.90
Return on equity:   -39.03%
Net income %:   -510.72%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy